N 17350
Alternative Names: N-17350; NEU-001 - Onchilles PharmaLatest Information Update: 04 Jul 2025
At a glance
- Originator Onchilles Pharma
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from preclinical studies in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Onchilles Pharma announces intention to initiate first-in-human clinical trials in Lung cancer, Skin cancer, Head and neck cancer, and Triple-negative breast cancer at the end of 2025
- 09 Apr 2024 Pharmacodynamics and adverse events data from preclinical trial in Cancer released by Onchilles Pharma